SM 20302

Drug Profile

SM 20302

Alternative Names: SM-20302

Latest Information Update: 30 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Developer Nonindustrial source; Sumitomo Pharmaceuticals
  • Class Antiplatelets; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary thrombosis; Thrombosis

Most Recent Events

  • 27 Sep 1999 Preclinical development for Coronary thrombosis in Japan (Unknown route)
  • 27 Sep 1999 Two preclinical studies have been added to the Thromboses and Ischaemic Heart Disease pharmacodynamics sections ,
  • 27 Sep 1999 Two preclinical studies have been added to the Thromboses pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top